동물용 항생제 및 항균제 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Animal Antibiotics and Antimicrobials Market was valued at USD 5.5 billion in 2025 and is estimated to grow at a CAGR of 1.6% to reach USD 6.5 billion by 2035.

Market growth is driven by the rising demand for animal protein, the increasing prevalence of infectious diseases in livestock, and the growing emphasis on animal health and productivity. Antibiotics and antimicrobials play a critical role in preventing, controlling, and treating bacterial infections across food-producing and companion animals. The expansion of intensive livestock farming, particularly in poultry, swine, and cattle, has significantly increased the need for effective antimicrobial therapies to reduce mortality rates and improve feed efficiency. Additionally, rising awareness among farmers regarding disease prevention and veterinary care is further supporting market growth globally.

The market growth is also influenced by evolving veterinary healthcare infrastructure and improved access to animal medicines in emerging economies. Governments and regulatory bodies are increasingly focusing on animal disease management to ensure food safety and public health, which continues to sustain demand for veterinary antimicrobials. While regulatory scrutiny around antimicrobial resistance (AMR) is tightening, the development of targeted and responsible-use antibiotics is supporting steady market expansion. Continuous advancements in formulation technologies and dosage delivery methods are also enhancing treatment efficacy while minimizing risks.

The tetracyclines segment generated USD 1.2 billion in 2025, owing to their broad-spectrum activity, cost-effectiveness, and widespread use in livestock treatment. Tetracyclines are commonly prescribed for respiratory, gastrointestinal, and systemic infections across multiple animal species. Their versatility, availability in multiple formulations such as powders, injectables, and oral solutions, and established clinical effectiveness make them a preferred choice among veterinarians and livestock producers. Despite increasing regulatory oversight, tetracyclines continue to maintain strong demand due to their proven reliability and ease of administration in large-scale farming operations.

The livestock segment is estimated to reach USD 4.5 billion by 2035, driven by the growing global consumption of meat, dairy, and eggs. Livestock producers rely heavily on antibiotics and antimicrobials to maintain herd health, prevent disease outbreaks, and ensure consistent productivity. Rising industrialization of animal farming, particularly in developing regions, has increased the need for disease prevention strategies to minimize economic losses. Additionally, growing investments in veterinary services and animal husbandry practices further strengthen the dominance of the livestock segment.

Asia Pacific Animal Antibiotics and Antimicrobials Market is estimated to grow at a CAGR of 2.2% through 2035, supported by rapid growth in livestock populations, expanding poultry production, and increasing demand for animal-derived food products. Countries such as China and India are witnessing strong growth due to large-scale farming operations and improving veterinary healthcare infrastructure. The region's increasing focus on food security, combined with rising awareness of animal disease management, continues to fuel demand. Additionally, favorable government initiatives supporting livestock health programs further reinforce Asia Pacific's leading position in the global market.

Key players operating in the Global Animal Antibiotics and Antimicrobials Market include Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim, Merck & Co. (MSD Animal Health), Ceva Sante Animale, Virbac, Dechra Pharmaceuticals, Bayer AG, Vetoquinol, and Phibro Animal Health Corporation. These companies are actively expanding their veterinary portfolios, strengthening distribution networks, and investing in R&D to develop safer and more effective antimicrobial solutions. Companies in the animal antibiotics and antimicrobials market are focusing on responsible product innovation and portfolio diversification to strengthen their market presence. Leading players are investing in research and development to introduce targeted antibiotics with improved efficacy and reduced antimicrobial resistance risks. Strategic partnerships with veterinary clinics, livestock producers, and regional distributors help expand market reach and improve product accessibility.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Animal type trends
  • 2.2.4 Mode of delivery trends
  • 2.2.5 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations
  • 2.4.1 Future outlook
  • 2.4.2 Strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing pet ownership rate
    • 3.2.1.2 Expanding livestock production
    • 3.2.1.3 Rise in R&D funding accelerating the research efforts
    • 3.2.1.4 Growing awareness for animal healthcare spurring demand for preventive treatment
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse effects of treatments
    • 3.2.2.2 Stringent regulatory requirements
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of aquaculture sector
    • 3.2.3.2 Growing adoption of digital and tele-veterinary services
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology landscape (Driven by Primary Research)
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends (Driven by Primary Research)
• 3.7 Pricing analysis (Driven by Primary Research)
• 3.8 Supply chain analysis (Driven by Primary Research)
• 3.9 Porter's analysis
• 3.10 Impact of AI and generative AI on the market
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
  • 4.2.4 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Penicillins
• 5.3 Tetracyclines
• 5.4 Sulfonamides
• 5.5 Macrolides
• 5.6 Aminoglycosides
• 5.7 Lincosamides
• 5.8 Fluoroquinolones
• 5.9 Cephalosporins
• 5.10 Other antibiotics and antimicrobial products

Chapter 6 Market Estimates and Forecast, By Animal Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Livestock animals
  • 6.2.1 Cattle
  • 6.2.2 Swine
  • 6.2.3 Poultry
  • 6.2.4 Fish
  • 6.2.5 Other livestock animals
• 6.3 Companion animals
  • 6.3.1 Dogs
  • 6.3.2 Cats
  • 6.3.3 Horses
  • 6.3.4 Other companion animals

Chapter 7 Market Estimates and Forecast, By Mode of Delivery, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Topical
• 7.4 Injections
• 7.5 Other modes of delivery

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospital pharmacy
• 8.3 Retail pharmacy
• 8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AdvaCare Pharma
• 10.2 Bimeda
• 10.3 Boehringer Ingelheim
• 10.4 Ceva Sante Animale
• 10.5 Dechra Pharmaceuticals
• 10.6 ECO Animal Health Group
• 10.7 Elanco Animal Health Incorporated
• 10.8 HIPRA
• 10.9 Lutim Pharma Private Limited
• 10.10 Meiji Holdings
• 10.11 Merck
• 10.12 Norbrook
• 10.13 Phibro Animal Health
• 10.14 Vetoquinol
• 10.15 Virbac
• 10.16 Zoetis
• 10.17 Zydus (Zyvet Animal Health)